There is evidence that brain noradrenergic systems participate in the feedback regulation of luteinizing hormone (LH) and prolactin (PRL) secretion by ovarian hormones. The present study tested the hypothesis that administration of ovarian hormones in regimens that decrease LH release would also decrease the turnover of norepinephrine (NE), while ovarian hormone treatments that stimulate LH or PRLsecretion would enhance the turnover NE in microdissected brain nuclei. Administration of estradiol to ovariectomized rats reduced circulating LH and decreased the turnover of NE in the periventricular nucleus. Treatment with estradiol, followed by progesterone or estradiol 72 h later enhanced the turnover of NE and of dopamine (DA) in the median eminence, and this was accompanied by elevations of LH and/or PRL. The dual estrogen treatment also increased NE turnover in the arcuate nucleus. Estradiol alone elevated DA turnover in the caudate nucleus and in the interstitial nucleus of the stria terminalis, and this was blocked by subsequent treatment with progesterone or estradiol. These findings indicate that activity in noradrenergic innervation to specific areas of the hypothalamus is altered by ovarian hormones. It is proposed that some of these changes may be involved in the feedback regulation of LH and PRL secretion by estradiol and progesterone.

Keywords:
Dopamine, Estradiol, Hypothalamus, Luteinizing hormone, Norepinephrine, Progesterone, Prolactin
This content is only available via PDF.
© 1982 S. Karger AG, Basel
1982
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.